These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 31701537)

  • 1. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
    Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
    Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
    Klünder B; Mohamed MF; Othman AA
    Clin Pharmacokinet; 2018 Aug; 57(8):977-988. PubMed ID: 29076110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
    Mohamed MF; Zeng J; Marroum PJ; Song IH; Othman AA
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):208-216. PubMed ID: 29688617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
    Mohamed MF; Trueman S; Feng T; Anderson J; Marbury TC; Othman AA
    J Clin Pharmacol; 2019 Jun; 59(6):856-862. PubMed ID: 30633369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation.
    Mohamed MF; Klünder B; Lacerda AP; Othman AA
    Clin Pharmacol Ther; 2020 Mar; 107(3):639-649. PubMed ID: 31594037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
    Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
    Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease.
    Bhatnagar S; Schlachter L; Eckert D; Stodtmann S; Liu W; Lacerda AP; Mohamed MF
    Clin Pharmacol Ther; 2024 Nov; 116(5):1240-1251. PubMed ID: 38982567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
    Mohamed MF; Gopalakrishnan S; Teixeira HD; Othman AA
    J Clin Pharmacol; 2021 May; 61(5):628-635. PubMed ID: 33156550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
    Trueman S; Mohamed MF; Feng T; Lacerda AP; Marbury T; Othman AA
    J Clin Pharmacol; 2019 Sep; 59(9):1188-1194. PubMed ID: 30973649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E; Thaçi D; Pangan AL; Hong HC; Papp KA; Reich K; Beck LA; Mohamed MF; Othman AA; Anderson JK; Gu Y; Teixeira HD; Silverberg JI
    J Allergy Clin Immunol; 2020 Mar; 145(3):877-884. PubMed ID: 31786154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.
    Mohamed MF; Minocha M; Trueman S; Feng T; Enejosa J; Fisniku O; Othman AA
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):299-306. PubMed ID: 32648334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn's disease.
    Faggiani I; D'Amico F; Bernardi F; Bencardino S; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Opin Drug Metab Toxicol; 2024 May; 20(5):297-305. PubMed ID: 38712496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
    Mohamed MF; Klünder B; Camp HS; Othman AA
    Clin Pharmacol Ther; 2019 Dec; 106(6):1319-1327. PubMed ID: 31194885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
    Mohamed MF; Beck D; Camp HS; Othman AA
    J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upadacitinib in Crohn's disease.
    Dignass A; Esters P; Flauaus C
    Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.